Neoadjuvante chemotherapie von kolorektalen lebermetastasen
Research output: Contribution to journal › Review article › Contributed › peer-review
Contributors
Abstract
Liver metastases can be resected with curative intention. If a resection of the metastases is not initially possible, it may be performed in some patients following neoadjuvant chemotherapy, resulting in a 5-year survival rate of 33%. Because tumor shrinkage is required for resection, and due to the correlation between resection rate and tumor response rate, a first line therapy with high response rates should be offered to patients. With this aim, the therapy is different from palliative therapy for metastatic colorectal cancer. It requires good interdisciplinary cooperation. High response rates may be achieved with a combination of antibodies and irinotecan or oxaliplatin containing infusional 5-FU combinations. Experimental approaches with more intensive regimens are under investigation. With standard chemotherapies such as FOLFOX or FOLFIRI, studies have shown that 10% of patients with metastatic colorectal cancer are secondarily resected; in studies with a neoadjuvant focus, a resection rate of 30% was observed.
Translated title of the contribution | Neoadjuvant chemotherapy for colorectal liver metastases |
---|
Details
Original language | German |
---|---|
Pages (from-to) | 571-582 |
Number of pages | 12 |
Journal | Onkologe |
Volume | 12 |
Issue number | 6 |
Publication status | Published - Jun 2006 |
Peer-reviewed | Yes |
External IDs
ORCID | /0000-0002-9321-9911/work/142251995 |
---|
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- Chemotherapy regime, FOLFIRI, FOLFOX, Liver metastases, Resection